Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy
Authors:
- 1 March 2015
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 94 (2) , 109-129
Abstract
No abstract availableKeywords
Funding Information
- Actelion Pharmaceuticals Ltd. (Switzerland)
- Encysive Pharmaceuticals Inc. (Houston, USA)
This publication has 55 references indexed in Scilit:
- Adiponectin Ameliorates Doxorubicin-induced Cardiotoxicity through Akt Protein-dependent MechanismJournal of Biological Chemistry, 2011
- Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based ChemotherapyJournal of Clinical Oncology, 2011
- Regulation of Blood Pressure and Salt Homeostasis by EndothelinPhysiological Reviews, 2011
- Pim-1 Kinase Protects Mitochondrial Integrity in CardiomyocytesCirculation Research, 2010
- Role of vasoactive peptides in high glucose-induced increased expression of Gαq/11 proteins and associated signaling in vascular smooth muscle cellsThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.Canadian Journal of Physiology and Pharmacology, 2010
- Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?European Heart Journal, 2008
- Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance–associated protein 2Biopharmaceutics & Drug Disposition, 2006
- Adriamycin-induced oxidative mitochondrial cardiotoxicityCell Biology and Toxicology, 2006
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Novel Antagonist of Endothelin ETB1 and ETB2 Receptors, BQ-788: Effects on Blood Vessel and Small IntestineBiochemical and Biophysical Research Communications, 1994